PURPOSE: Children with acute lymphoblastic leukemia (ALL) are at risk for impaired bone accrual. This peripheral quantitative computed tomography study assessed changes in bone mineral density (BMD) and structure after completion of ALL treatment. METHODS: Fifty ALL participants, ages 5-22 yr, were enrolled within 2 yr (median 0.8 yr) after completing ALL therapy. Tibia peripheral quantitative computed tomography scans were performed at enrollment and 12 months later. Age-, sex-, and race-specific Z-scores for trabecular BMD (TrabBMD), cortical BMD (CortBMD), and cortical area (CortArea) were generated based on more than 650 reference participants. Multivariable linear regression models examined determinants of changes in Z-scores. RESULTS: At enrollment, mean TrabBMD (-1.03±1.34) and CortBMD (-0.84±1.05) Z-scores were low (both P<0.001) compared with reference participants. TrabBMD and CortBMD Z-scores increased to -0.58±1.41 and -0.51±0.91 over 1 yr, respectively (both P<0.001). Changes in cortical outcomes varied according to the interval since completion of therapy. Among those enrolled less than 6 months after therapy, CortArea Z-scores increased and CortBMD Z-scores decreased (both P<0.01). Among those enrolled 6 months or more after therapy, CortArea Z-scores did not change and CortBMD Z-scores increased (P<0.01). Changes in CortArea and CortBMD Z-scores were inversely associated (r=-0.32, P<0.001). Cumulative glucocorticoid exposure, leukemia risk status, and antimetabolite chemotherapy were not associated with outcomes. CONCLUSION: TrabBMD was low after completion of ALL therapy and improved significantly. Early increases in cortical dimensions were associated with declines in CortBMD; however, participants further from ALL therapy demonstrated stable cortical dimensions and increases in CortBMD, potentially reflecting the time necessary to mineralize newly formed bone.
PURPOSE:Children with acute lymphoblastic leukemia (ALL) are at risk for impaired bone accrual. This peripheral quantitative computed tomography study assessed changes in bone mineral density (BMD) and structure after completion of ALL treatment. METHODS: Fifty ALL participants, ages 5-22 yr, were enrolled within 2 yr (median 0.8 yr) after completing ALL therapy. Tibia peripheral quantitative computed tomography scans were performed at enrollment and 12 months later. Age-, sex-, and race-specific Z-scores for trabecular BMD (TrabBMD), cortical BMD (CortBMD), and cortical area (CortArea) were generated based on more than 650 reference participants. Multivariable linear regression models examined determinants of changes in Z-scores. RESULTS: At enrollment, mean TrabBMD (-1.03±1.34) and CortBMD (-0.84±1.05) Z-scores were low (both P<0.001) compared with reference participants. TrabBMD and CortBMD Z-scores increased to -0.58±1.41 and -0.51±0.91 over 1 yr, respectively (both P<0.001). Changes in cortical outcomes varied according to the interval since completion of therapy. Among those enrolled less than 6 months after therapy, CortArea Z-scores increased and CortBMD Z-scores decreased (both P<0.01). Among those enrolled 6 months or more after therapy, CortArea Z-scores did not change and CortBMD Z-scores increased (P<0.01). Changes in CortArea and CortBMD Z-scores were inversely associated (r=-0.32, P<0.001). Cumulative glucocorticoid exposure, leukemia risk status, and antimetabolite chemotherapy were not associated with outcomes. CONCLUSION: TrabBMD was low after completion of ALL therapy and improved significantly. Early increases in cortical dimensions were associated with declines in CortBMD; however, participants further from ALL therapy demonstrated stable cortical dimensions and increases in CortBMD, potentially reflecting the time necessary to mineralize newly formed bone.
Authors: Rachel I Gafni; Edward F McCarthy; Tracy Hatcher; Jodi L Meyers; Nozomu Inoue; Chitra Reddy; Martina Weise; Kevin M Barnes; Veronica Abad; Jeffrey Baron Journal: FASEB J Date: 2002-03-26 Impact factor: 5.191
Authors: Sogol Mostoufi-Moab; Jill P Ginsberg; Nancy Bunin; Babette Zemel; Justine Shults; Mary B Leonard Journal: J Bone Miner Res Date: 2012-04 Impact factor: 6.741
Authors: S C Kaste; D Jones-Wallace; S R Rose; J M Boyett; R H Lustig; G K Rivera; C H Pui; M M Hudson Journal: Leukemia Date: 2001-05 Impact factor: 11.528
Authors: P M Crofton; S F Ahmed; J C Wade; R Stephen; M W Elmlinger; M B Ranke; C J Kelnar; W H Wallace Journal: J Clin Endocrinol Metab Date: 1998-09 Impact factor: 5.958
Authors: Babette S Zemel; Mary B Leonard; Andrea Kelly; Joan M Lappe; Vicente Gilsanz; Sharon Oberfield; Soroosh Mahboubi; John A Shepherd; Thomas N Hangartner; Margaret M Frederick; Karen K Winer; Heidi J Kalkwarf Journal: J Clin Endocrinol Metab Date: 2010-01-26 Impact factor: 5.958
Authors: Elizabeth A Cummings; Jinhui Ma; Conrad V Fernandez; Jacqueline Halton; Nathalie Alos; Paivi M Miettunen; Jacob L Jaremko; Josephine Ho; Nazih Shenouda; Mary Ann Matzinger; Brian Lentle; David Stephure; Robert Stein; Ann Marie Sbrocchi; Celia Rodd; Bianca Lang; Sara Israels; Ronald M Grant; Robert Couch; Ronald Barr; John Hay; Frank Rauch; Kerry Siminoski; Leanne M Ward Journal: J Clin Endocrinol Metab Date: 2015-07-14 Impact factor: 5.958
Authors: Elizabeth A Streeten; Sheila Ramirez; Myrto Eliades; Sarada Jaimungal; Sruti Chandrasekaran; Ryan Kathleen; D Holmes Morton; Erik G Puffenberger; Rita Herskovitz; Mary B Leonard Journal: Bone Date: 2015-04-16 Impact factor: 4.398
Authors: David R Weber; Rebecca J Gordon; Jennifer C Kelley; Mary B Leonard; Steven M Willi; Jacquelyn Hatch-Stein; Andrea Kelly; Oksana Kosacci; Olena Kucheruk; Mirna Kaafarani; Babette S Zemel Journal: J Clin Endocrinol Metab Date: 2019-10-01 Impact factor: 5.958
Authors: Mark D DeBoer; Arthur M Lee; Kirabo Herbert; Jin Long; Meena Thayu; Lindsay M Griffin; Robert N Baldassano; Lee A Denson; Babette S Zemel; Michelle R Denburg; Rita Herskovitz; Mary B Leonard Journal: J Clin Endocrinol Metab Date: 2018-03-01 Impact factor: 5.958
Authors: Sogol Mostoufi-Moab; Andrea Kelly; Jonathan A Mitchell; Joshua Baker; Babette S Zemel; Jill Brodsky; Jin Long; Mary B Leonard Journal: Bone Date: 2018-04-19 Impact factor: 4.398
Authors: J G Gurney; S C Kaste; W Liu; D K Srivastava; W Chemaitilly; K K Ness; J Q Lanctot; R P Ojha; K A Nottage; C L Wilson; Z Li; L L Robison; M M Hudson Journal: Pediatr Blood Cancer Date: 2014-02-28 Impact factor: 3.167
Authors: Lindsay M Griffin; Meena Thayu; Robert N Baldassano; Mark D DeBoer; Babette S Zemel; Michelle R Denburg; Lee A Denson; Justine Shults; Rita Herskovitz; Jin Long; Mary B Leonard Journal: J Clin Endocrinol Metab Date: 2015-04-28 Impact factor: 5.958
Authors: Anne Tsampalieros; Carol K L Lam; Jenna C Spencer; Meena Thayu; Justine Shults; Babette S Zemel; Rita M Herskovitz; Robert N Baldassano; Mary B Leonard Journal: J Clin Endocrinol Metab Date: 2013-05-20 Impact factor: 5.958